Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 0.81 |
| ▸ | PARP2 | Q9UGN5 | 14/20 | 0.81 |
| ▸ | PARP3 | Q9Y6F1 | 14/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL27759055 | 0.94 | PARP1 (0.72) | PARP1PARP2PARP3 | |
| Trifluoroacetic Acid SCHEMBL2267277 | 0.94 | PARP1 (0.72) | PARP1PARP2PARP3 | |
| SCHEMBL2265683 | 0.90 | PARP1 (1.00) | PARP1PARP2PARP3 | |
| SCHEMBL4769704 | 0.85 | PARP1 (0.74) | PARP1PARP2PARP3 | |
| SCHEMBL2262015 | 0.83 | PARP1 (0.72) | PARP1PARP2PARP3 | |
| SCHEMBL30875676 | 0.82 | PARP1 (0.83) | PARP1PARP2PARP3 | |
| SCHEMBL2268369 | 0.82 | PARP1 (0.73) | PARP1PARP2PARP3 | |
| SCHEMBL30875666 | 0.82 | PARP1 (0.73) | PARP1PARP2PARP3 | |
| Trifluoroacetic Acid SCHEMBL2268500 | 0.80 | PARP1 (0.66) | PARP1PARP2PARP3 | |
| SCHEMBL2267556 | 0.80 | PARP1 (1.00) | PARP1PARP2PARP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | FUKANG (SHANGHAI) HEALTH TECHNOLOGY CO., LTD (CN) | 2024-01-18 | — | — | US | claimed |
| EP-4112049-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | Fukang (Shanghai) Health Technology Co., Ltd. (CN) | 2023-01-04 | — | — | EP | claimed |
| CN-113288892-B | Use of poly ADP-ribose polymerase inhibitors against coronaviruses | 甫康（上海）健康科技有限责任公司 | 2024-04-26 | — | — | CN | disclosed |
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | FUKANG (SHANGHAI) HEALTH TECHNOLOGY CO., LTD (CN) | 2024-01-18 | — | — | US | disclosed |
| EP-4112049-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | Fukang (Shanghai) Health Technology Co., Ltd. (CN) | 2023-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | PARP3, PARP1, PARP4 | PARP1 2/4885PARP2 14/4885PARP3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.